Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2008-008301-22-IT
EUCTR2008-008301-22-IT
Active, Not Recruiting
N/A

PHASE II CLINICAL STUDY OF THE DIAGNOSTIC EFFICACY OF [18F]FLUOROETHYILCHOLINE ([18F]FECh) IN PATIENTS WITH PROSTATE CANCER - ND

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI0 sitesJanuary 22, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Status
Active, Not Recruiting
Last Updated
13 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 22, 2009
End Date
TBD
Last Updated
13 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Sponsor
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Eligibility Criteria

Inclusion Criteria

  • •\-adult male patients with a) known prostate cancer (biopsy) and eligible for surgical treatment; b) biochemical recurrence of prostate cancer after prostatectomy (PSA\> 0\.2 ng/ml)
  • •\-availability to participate to the study (informed consent);
  • •\-patients suitable for the diagnostic procedure (PET\-TC with 18F\-FECh);
  • •\-patients with life expectancy \> 2 months.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •\-patients not suitable for the study protocol;
  • •\-patients with life expectancy \< 2 months

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not Yet Recruiting
Phase 2
Phase II study of preliminary diagnostic performance of [68Ga]-NeoBOMB1 in adult patients with malignancies known to overexpress Gastrin Releasing Peptide ReceptorCancerMalignancies known to overexpress GRPR10027655
NL-OMON46627Advanced Accelerator Applications International S.A.10
Active, Not Recruiting
Phase 1
Study of [68Ga]-NeoBOMB1 imaging in patients with malignancies known to overexpress GRPRMalignancies known to overexpress Gastrin-Releasing Peptide ReceptorsMedDRA version: 20.0 Level: PT Classification code 10006187 Term: Breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10041067 Term: Small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2017-003432-37-ATAdvanced Accelerator Applications International SA50
Active, Not Recruiting
Phase 1
Study to assess the efficacy and safety of the study drug atezolizumab in combination with paclitaxel and bevacizumab in patients with previously untreated advanced or metastatic triple negative breast cancer.
EUCTR2019-001503-20-FRMedica Scientia Innovation Research (MedSIR)100
Active, Not Recruiting
Phase 1
Study to assess the efficacy and safety of the study drug atezolizumab in combination with paclitaxel and bevacizumab in patients with previously untreated advanced or metastatic triple negative breast cancer.Advanced or metastatic triple-negative breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2019-001503-20-ITMEDICA SCIENTIA INNOVATION RESEARCH, ARO100
Active, Not Recruiting
Phase 1
Study to assess the efficacy and safety of the study drug atezolizumab in combination with paclitaxel and bevacizumab in patients with previously untreated advanced or metastatic triple negative breast cancer.Advanced or metastatic triple-negative breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2019-001503-20-DEMedica Scientia Innovation Research S. L. (MedSIR)100